The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Open accessAbstract
The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, a total of 385,853 persons had received at least one vaccine dose and 265,410 had completed the two doses. Vaccination scale-up occurred as Qatar was undergoing its second and third waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which were triggered by expansion of the B.1.1.7 variant (starting in mid-January 2021) and the B.1.351 variant (starting in mid-February 2021). The B.1.1.7 wave peaked during the first week of March, and the rapid expansion of B.1.351 started in mid-March and continues to the present day. Viral genome sequencing conducted from February 23 through March 18 indicated that 50.0% of cases of Covid-19 in Qatar were caused by B.1.351 and 44.5% were caused by B.1.1.7. Nearly all cases in which virus was sequenced after March 7 were caused by either B.1.351 or B.1.1.7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The test-negative design, which does not assume that a lack of a positive test equals a negative test and somewhat adjusts for testing volume, attempts to better mitigate this bias and is the reason we chose this method for this analysis”
From Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine (2022) · cites this paper as [25]
In the citing paper
“Reduced protection against any symptomatic COVID-19 disease caused by the B.1.351 variant of concern (now known as the Beta variant) has been reported from clinical trials18, but emerging data suggest that there remains high protection against the important end points of severe disease and hospitalization99.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [99]
In the citing paper
“These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4,14 and to minimize different types of potential bias, as informed by earlier analyses in the same population.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“Effectiveness was assessed with the use of an observational, test-negative, case–control design rather than a design in which cohorts of individual persons were followed up. However, the cohort study design applied earlier to the same population yielded findings similar to those of the test-negative design.14,15,31”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case–control design36,38,39, supporting the validity of this standard approach in assessing vaccine effectiveness11,12,36,40.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [38]
In the citing paper
“As compared with recent findings from Qatar on the effectiveness of the BNT162b2 vaccine against the alpha and beta variants,17 our findings suggest that effectiveness against the delta variant after a full vaccination course lies somewhere between these two.”
From Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (2021) · cites this paper as [17]
In the citing paper
“In cohort studies from Israel and Qatar, the BNT162b vaccine also retained greater than 90% efficacy against this variant 210,211 (TABLe 2).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“In the previously cited Qatar cohort study, the efficacy of BNT162b against the Beta variant was estimated to be 72%, which was 15% lower than that for the Alpha variant 211 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“Likewise, clinical studies have reported somewhat reduced efficacy and effectiveness against the B.1.1.7, B.1.351, and B.1.617.2 variants (10–12).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [10]
In the citing paper
“The effectiveness of the BNT162b2 vaccine against the Beta variant was measured shortly after the population of Qatar had been vaccinated, whereas the effectiveness of BNT162b2 against the Delta variant was conducted several months after the second dose, which could be one of the reasons for low effectiveness of BNT162b2 against the Delta variant.404,405”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [405]
In the citing paper
“Beta [as a benchmark for partially reduced neutralization (7) without major impact on effectiveness (19, 20)]”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [19]
In the citing paper
“Coronavirus disease 2019 (Covid-19) vaccines are highly effective against symptomatic disease and, more so, against severe disease and fatal outcomes caused by the original strain of SARS-CoV-2 as well as the alpha (B.1.1.7) variant that predominated in early 2021.”
From Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 879
Li, X., Liu, J., Li, W., Peng, Q., Li, M., Ying, Z., Zhang, Z., Liu, X., Wu, X., Zhao, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1142394 · Cited by 7
Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study
Mathema, B., Chen, L., Chow, K. F., Zhao, Y., Zody, M. C., Mediavilla, J. R., Cunningham, M. H., Composto, K., Lee, A., Oschwald, D. M., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01882-21 · Cited by 7
Mandala, W. L., & Liu, M. K. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.797117 · Cited by 7
Nguyen, L. B. L., Bauer, R., Lesieur, Z., Galtier, F., Duval, X., Vanhems, P., Lainé, F., Tattevin, P., Durier, C., & Launay, O. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2021.12.002 · Cited by 7
COVID-19 Vaccination in Children: An Open Question
Bardanzellu, F., Campagnani, G., Pintus, M. C., Fanos, V., & Marcialis, M. A. (2021) · Current Pediatric Reviews · doi:10.2174/1573396318666211220093111 · Cited by 8
In vivo (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray
Friedland, P. L., Tucker, S., Goodall, S., Julander, J. G., Mendenhall, M., Molloy, P., de Jong, D. M., Musungaie, D. B., Sikazwe, C. T., Panta, K., et al. (2022) · Australian Journal of Otolaryngology · doi:10.21037/ajo-21-40 · Cited by 7
Advances in COVID-19 Vaccines and New Coronavirus Variants
Liu, M., & Li, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.888631 · Cited by 7
Suzuki, Y., Shibata, Y., Minemura, H., Nikaido, T., Tanino, Y., Fukuhara, A., Kanno, R., Saito, H., Suzuki, S., Ishii, T., et al. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.71132 · Cited by 7
Transition of Antibody Titers after SARS-CoV-2 mRNA Vaccination in Japanese Healthcare Workers
Kitabatake, M., Ouji-Sageshima, N., Sonobe, S., Furukawa, R., Konda, M., Hara, A., Aoki, H., Suzuki, Y., Imakita, N., Nakano, A., et al. (2022) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2022.041 · Cited by 7
Cooper, D. J., Lear, S. E., Sithole, N., Shaw, A. S., Stark, H., Ferris, M., Bradley, J. R., Maxwell, P. H., Goodfellow, I., Weekes, M. P., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063159 · Cited by 7
COVID-19 Health Passes: Practical and Ethical Issues
Millán, G. M. O. (2023) · Journal of Bioethical Inquiry · doi:10.1007/s11673-022-10227-2 · Cited by 8
Butt, A. A., Peng, Y., Shaikh, O. S., Omer, S. B., Mayr, F., & Talisa, V. B. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad195 · Cited by 7
Self-citationHerd immunity: challenges and the way forward in Korea
Oh, J., Kim, S., Ryu, B., Shin, M., & Kim, B. I. (2021) · Epidemiology and Health · doi:10.4178/epih.e2021054 · Cited by 7
Hikichi, T., Sakamoto, M., Harada, M., Saito, M., Yamane, Y., Tokumura, K., & Nakamura, Y. (2022) · Journal of Human Genetics · doi:10.1038/s10038-022-01013-4 · Cited by 7
Modified mRNA-Based Vaccines Against Coronavirus Disease 2019
Wang, A. Y. L. (2022) · Cell Transplantation · doi:10.1177/09636897221090259 · Cited by 7
Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants
Wang, E. J. D., & Chakraborty, A. K. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010563 · Cited by 7
Wang, C., Dinesh, R. K., Qu, Y., Rustagi, A., Cousins, H. C., Zengel, J. R., Zhang, T., Magazine, N., Guo, Y., Hall, T. O., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.01.450475 · Cited by 8
Chemaitelly, H. S., Akhtar, N., Jerdi, S. A., Kamran, S., Joseph, S., Morgan, D., Uy, R. S., Abid, F. B., Al‐Khal, A., Abou‐Samra, A., et al. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2596676 · Cited by 6
Self-citationJiang, J., Lau, E. H. Y., Zhou, Z., Yin, G., Lin, Y., Cowling, B. J., & Lam, K. F. (2024) · Vaccines · doi:10.3390/vaccines12091014 · Cited by 6
A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines
Banerjee, S., Banerjee, D., Singh, A., & Saharan, V. A. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02247-3 · Cited by 6
Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview
Hadizadeh, N., Naderi, M., Khezri, J., Yazdani, M., Shamsara, M., & Hashemi, E. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01002-6 · Cited by 7
Lunderberg, J. M., Dutta, S., Collier, A.-R. Y., Lee, J.-S., Hsu, Y., Wang, Q., Zheng, W., Hao, S., Zhang, H., Feng, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032574 · Cited by 7
Raikhel, A. V., Blau, K., Alberty, K., Cornia, P. B., Rodriguez, R. A., Steinberg, K. P., & Wu, C. (2022) · American Journal of Medical Quality · doi:10.1097/jmq.0000000000000094 · Cited by 6
Effects of Second Dose of SARS-CoV-2 Vaccination on Household Transmission, England
Zaidi, A., Harris, R., Hall, J., Woodhall, S. C., Andrews, N. J., Dunbar, K., Bernal, J. L., & Dabrera, G. (2023) · Emerging infectious diseases · doi:10.3201/eid2901.220996 · Cited by 6
COVID-19 Vaccines—All You Want to Know
Shishido, A. A., Barnes, A. H., Narayanan, S., & Chua, J. V. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1759779 · Cited by 6
Profiling of Early Immune Responses to Vaccination Using THP-1-Derived Dendritic Cells
Ye, L., Li, P., Wang, M., Wu, F., Han, S., & Ma, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105509 · Cited by 6
COVID-19: State of the Vaccination
Fenton, C., & Lamb, Y. N. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00869-4 · Cited by 6
SARS-CoV-2 transmissibility compared between variants of concern and vaccination status
Wang, L., Didelot, X., Bi, Y., & Gao, G. F. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab594 · Cited by 8
Putra, W. F. (2022) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v28i1.2243 · Cited by 6
Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm
Abusalah, M. A. H., Khalifa, M., Al-Hatamleh, M. A. I., Jarrar, M., Mohamud, R., & Yean, C. Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030386 · Cited by 6
Zhu, K.-L., Gao, H., Lin, Y., Rong, J., Li, Y., Zhang, Z., Jiang, P., Duan, L., Wang, G., Dai, E., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac149 · Cited by 6
Li, J., Li, Z., Zhu, Y., Zhou, L., & Zhu, F. (2022) · Zoonoses · doi:10.15212/zoonoses-2022-0025 · Cited by 6
Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
Gasperina, D. D., Veronesi, G., Castelletti, C. M., Varchetta, S., Ottolini, S., Mele, D., Ferrari, G., Shaik, A. K. B., Celesti, F., Dentali, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813728 · Cited by 6
Louis, G., Belveyre, T., Goetz, C., Gibot, S., Dunand, P., Conrad, M., Gaci, R., Gette, S., Ouamara, N., Perez, P., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.828402 · Cited by 6
Biswas, S., Mahmud, S., Mita, M. A., Afrose, S., Hasan, M. R., Paul, G. K., Shimu, M. S. S., Uddin, M. S., Zaman, S., Park, M. N., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.825245 · Cited by 6
Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikesPreprint
Liu, Y., Liu, J., Zou, J., Ren, P., Weaver, S. C., Xie, X., & Shi, P. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.02.458740 · Cited by 6
Boloko, L., Lifson, A., Little, F., de Wet, T. J., Papavarnavas, N., Marais, G. J. K., Hsiao, M., Rosslee, M.-J., Doolabh, D., Iranzadeh, A., et al. (2021) · medRxiv · doi:10.1101/2021.11.04.21265916 · Cited by 6
Global Estimates of COVID‐19 Morbidity and Mortality: A Cohort Study and Mathematical Model Analysis
Ayoub, H. H., Chemaitelly, H. S., & Abu-Raddad, L. J. (2025) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70154 · Cited by 5
Self-citationPatel, N., Bouchard, J. L., Oliver, M. B., Badowski, M. E., Carreno, J. J., & the Society of Infectious Diseases Pharmacists (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2622 · Cited by 5
Rajpal, V. R., Sharma, S., Kumar, A., Vaishnavi, S., Singh, A., Sehgal, D., Tiwari, M., Goel, S., & Raina, S. N. (2022) · Future Virology · doi:10.2217/fvl-2021-0267 · Cited by 5
Ikuse, T., Aizawa, Y., Shobukawa, Y., Tomiyama, N., Nakayama, H., Takahashi, M., Muto, K., Hasegawa, S., Takahashi, M., Kon, M., et al. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003607 · Cited by 5
Di, Y., Lew, J. M., Goncin, U., Radomska, A., Rout, S. S., Gray, B. E. T., Machtaler, S., Falzarano, D., & Lavender, K. J. (2022) · Viruses · doi:10.3390/v14102272 · Cited by 6
Worp, N., Subissi, L., Perkins, M. D., Kerkhove, M. D. V., Agrawal, A., Chand, M. A., van Beek, J., Munnink, B. B. O., & Koopmans, M. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00179-9 · Cited by 5
Morris, J. S. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae280 · Cited by 5
The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
Tosta, E. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00014 · Cited by 5
Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission
Makhoul, M., Abu-Hijleh, F. M., Ayoub, H. H., Seedat, S., Chemaitelly, H. S., & Abu-Raddad, L. J. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100567 · Cited by 5
Self-citationTakagi, A., & Matsui, M. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01659-21 · Cited by 5
Nava, G. R., Egoryan, G., Dong, T., Zhang, Q., Hyser, E., Poudel, B., Yanez‐Bello, M. A., Trelles-Garcia, D. P., Chung, C. W., Pyakuryal, B., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07555-4 · Cited by 5
Amati, R., Piumatti, G., Franscella, G., Buttaroni, P., Camerini, A.-L., Corna, L., Levati, S., Fadda, M., Fiordelli, M., Annoni, A. M., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043703 · Cited by 5
Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
Akamine, C. M., & Sahly, H. M. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.007 · Cited by 5
Ginseng Protects ACE2-Transgenic Mice from SARS-CoV-2 Infection
Seo, S. H. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2706180 · Cited by 5
Changing Dynamics of SARS-CoV-2: A Global Challenge
Chugh, A., Khurana, N., Verma, K., Sehgal, I., Rolta, R., Vats, P., Phartyal, R., Salaria, D., Kaushik, N., Choi, E. H., et al. (2022) · Applied Sciences · doi:10.3390/app12115546 · Cited by 5
Distorted Human Decision-Making as a Critical Aspect of Pandemic Planning and Preparedness.
Poland, C. M., Ratishvili, T., & Poland, G. A. (2022) · PubMed Central · Cited by 5
Alkadi, M. M., Hamad, A., Ghazouani, H., Elshirbeny, M. F., Ali, M. Y., Ghonimi, T. A. L., Ibrahim, R., Abuhelaiqa, E. A., Abou‐Samra, A., Al-Malki, H. A., et al. (2022) · Vaccines · doi:10.3390/vaccines11010049 · Cited by 5
Self-citationSheikhi, F., & Kowsari, Z. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282624 · Cited by 5
Lakhia, R. T., & Trivedi, J. R. (2024) · F1000Research · doi:10.12688/f1000research.145771.1 · Cited by 5
A review of SARS-CoV-2 virology, vaccines, variants and their impact on the COVID-19 pandemic
Hirahata, T., Quraish, R. U., Quraish, A. U., & Quraish, S. U. (2024) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000393 · Cited by 4
Membrane-wide screening identifies potential tissue-specific determinants of SARS-CoV-2 tropism
Dinesh, R. K., Wang, C., Qu, Y., Rustagi, A., Cousins, H. C., Zengel, J. R., Wang, X., Barnard, T. R., Johnson, W. A., Xu, G., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013157 · Cited by 5
Huang, Q., Zeng, J., Lang, Q., Gao, F., Liu, D., Tian, S., Shi, R., Luo, L., Wang, H., Hu, L., et al. (2022) · 中国科学通报：英文版 · doi:10.1016/j.scib.2022.05.010 · Cited by 4
Obach, D., Solastie, A., Liedes, O., Vara, S., Krzyżewska, E., Brinkmann, L., Haveri, A., Hammer, C. C., Dub, T., Meri, S., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.679 · Cited by 4
Chua, J. X., Durrant, L. G., Chok, Y. L., & Lai, O. M. (2022) · iScience · doi:10.1016/j.isci.2022.105379 · Cited by 4
Cao, C., Mehmood, A., & Li, D. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2274514 · Cited by 4
Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins
Kumar, S., Dasgupta, S., Sajadi, M. M., Snyder, G. A., DeVico, A. L., & Ray, K. (2024) · Viruses · doi:10.3390/v16030407 · Cited by 4
Jitsuk, N. C., Chadsuthi, S., & Modchang, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28042 · Cited by 4
Evolutionary dynamics of voluntary vaccination for imperfect multi-efficacy vaccines
Hu, S., Liu, Y., & Wu, B. (2024) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2023.0743 · Cited by 4
Analysis of the immune response in COVID-19
Hromić‐Jahjefendić, A., & Aljabali, A. A. A. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.10.004 · Cited by 4
Sorbo, L. D., Acconcia, C., Salvatore, M. M., Fusco, G., Vasinioti, V. I., Lucente, M. S., Zhu, L., Pratelli, A., Russo, L., Andolfi, A., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13030579 · Cited by 4
Alfaro, S., Sen-Crowe, B., McKenny, M., & Elkbuli, A. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102709 · Cited by 4
Kazama, I. (2021) · Clinical and Molecular Allergy · doi:10.1186/s12948-021-00162-9 · Cited by 4
Iqbal, H., Umair, M., Rizvi, S. A., & Cheema, M. A. (2022) · BioMed · doi:10.3390/biomed2020015 · Cited by 4
SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
Syahniar, R., & Kharisma, D. S. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.2.173 · Cited by 4
SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_7 · Cited by 4
Xu, X., Hong, Y., Chen, E., Wang, Y., Ma, B., Li, J., Su, W., Zhou, Y., & Zhang, M. (2022) · Vaccines · doi:10.3390/vaccines10122110 · Cited by 5
Dai, Y.-C., Lin, Y.-C., Ching, L. L., Tsai, J., Ishikawa, K. M., Tsai, W.-Y., Chen, J. J., Nerurkar, V. R., & Wang, W. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04081-22 · Cited by 4
Younes, S. N., Nicolai, E., Al‐Sadeq, D. W., Younes, N., Al-Dewik, N. I. E., Abou-Saleh, H., Halawa, B. Y. A., Eid, A. H., Pieri, M., Liu, N., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.08.009 · Cited by 4
Self-citationAhmed, N., Athavale, A., Tripathi, A. H., Subramaniam, A., Upadhyay, S. K., Pandey, A. K., Rai, R. C., & Awasthi, A. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13345 · Cited by 4
Wearing a mask does indeed matter: Lessons from the 2021 influenza infection season
Kobayashi, K., & Noguchi, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.06.021 · Cited by 4
A surrogate cell‐based SARS‐CoV‐2 spike blocking assay
Schuh, W., Baus, L., Steinmetz, T. D., Schulz, S. R., Weckwerth, L., Roth, E. A., Hauke, M., Krause, S. K., Morhart, P., Rauh, M., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149302 · Cited by 5
Yu, Y., Lau, J. T. F., & Lau, M. M. C. (2021) · Vaccines · doi:10.3390/vaccines9121414 · Cited by 4
An Analysis of Conspiracy Beliefs of Covid-19 Vaccination in Ghana
Baffoe, G. A., & Watson-Nortey, N. K. L. (2021) · Advances in Journalism and Communication · doi:10.4236/ajc.2021.94014 · Cited by 4
Yan, Z., Yang, M., & Lai, C. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.858006 · Cited by 4
Koç, İ. (2022) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2022.j041 · Cited by 4
A Comprehensive Review on Efficacy and Adverse Events Associated With Different Covid-19 Vaccines
Borra, S. S., Narenthiran, C. K., Kumar, D. M., Ayilya, M., & Krishnamoorthy, S. G. (2022) · Jordan Journal of Pharmaceutical Sciences · doi:10.35516/jjps.v15i2.326 · Cited by 4
Avagyan, S., Zilfyan, A., & Muradyan, A. A. (2022) · THE NEW ARMENIAN MEDICAL JOURNAL · doi:10.56936/18290825-2022.16.2-14 · Cited by 4
BNT162b2 mRNA COVID-19 Vaccine Elicited Antibody Responses in COVID-19-naive Subjects
Lau, C. S., Phua, S. K., Liang, Y. L., Lin, M., & Aw, T. C. (2021) · Journal of Experimental Pathology · doi:10.33696/pathology.2.023 · Cited by 4
Bar‐On, Y. M., Noor, Ε., Gottlieb, N., Sigal, A., & Milo, R. (2021) · medRxiv · doi:10.1101/2021.06.06.21258429 · Cited by 4
A Rapid Saliva Test for Monitoring Immune Protection against SARS -CoV-2 and its VariantsPreprint
Momyer, V. S. A., Dixon, S., Liu, Q. J., Wee, B., Chen, T., Petropoulos, A. E., & Sang, L. J. (2021) · medRxiv · doi:10.1101/2021.07.09.21260224 · Cited by 4
Neutralization of VOCs including Delta one year post COVID-19 or vaccinePreprint
Havervall, S., Marking, U. W., Gordon, M., Ng, H., Greilert‐Norin, N., Lindbo, S., Blom, K. G., Nilsson, P., Phillipson, M., Klingström, J., et al. (2021) · medRxiv · doi:10.1101/2021.08.12.21261951 · Cited by 4
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-19168-3 · Cited by 3
Self-citationOh, D., Hölzer, M., Börnigen, D., Paraskevopoulou, S., Duwe, S. C., Budt, M., Kerber, R., Mikołajewska, A., Böttcher, S., Seifried, J., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01093-1 · Cited by 4
Comportamiento y salud. Investigación traslacional y aplicada
González-Becerra, V. H., González-Cantero, J. O., & Gutiérrez, A. A. (2021) · Qartuppi eBooks · doi:10.29410/qtp.21.17 · Cited by 4
Arnold, C. E., Voegtly, L. J., Stefanov, E. K., Lueder, M. R., Luquette, A. E., Miller, R. H., Miner, H. L., Bennett, A. J., Glang, L. A., McGinnis, T. N., et al. (2022) · Viruses · doi:10.3390/v14091918 · Cited by 3
Ravindran, R. K., Kang, H., McReynolds, C. B., Sanghar, G. K., Chang, W. L. W., Ramasamy, S., Kolloli, A., Kumar, R., Subbian, S., Hammock, B. D., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287377 · Cited by 3
Immune histories and natural infection protection during the omicron era
Chemaitelly, H. S., Ayoub, H. H., Bobrovitz, N., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00974-9 · Cited by 3
Self-citationVesin, B., Authié, P., Blanc, C., Fert, I., Noirat, A., Chevalier, F. L., Yu, W., Ku, M., Nemirov, K., Anna, F., et al. (2022) · Vaccines · doi:10.3390/vaccines11010012 · Cited by 3
Soon, H. I., Abdullah, A. A., Nishizaki, H., Mashor, . Y., Kamarudin, L. M., Mohamed‐Hussein, Z., Mohamed, Z., & Ang, W. C. (2024) · International Journal of ADVANCED AND APPLIED SCIENCES · doi:10.21833/ijaas.2024.06.023 · Cited by 3
Abdella, W. S., Selim, A. N., Diab, S., Qobeia, E., & Elgazzar, A. F. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-61939-7_9 · Cited by 3
Katoh, M., & Katoh, M. (2021) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2021.720577 · Cited by 3
Which are the best coronavirus disease 2019 vaccines?
Omrani, A. S., & Tleyjeh, I. M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.08.012 · Cited by 4
Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments
Abdurrahman, L., Fang, X., & Zhang, Y. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666211013121831 · Cited by 4
Metadata
- Authors
- Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07-08
- Volume
- 385
- Issue
- 2
- Pages
- 187-189
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8117967
- OpenAlex
- W3157162195
- Cited by
- 899
- References
- 4
- Citations by year
- 2026: 16 · 2025: 32 · 2024: 46 · 2023: 92 · 2022: 358 · 2021: 351
- FWCI
- 67.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, the Ministry of Public Health and Hamad Medical Corporation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, COVID-19 vaccine efficacy, SARS-CoV-2 variants, B.1.1.7 variant, B.1.351 variant, Omicron variant, vaccination campaigns, viral genome sequencing, COVID-19 waves
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Qatar, Cohort Studies, Case-Control Studies, Polymerase Chain Reaction, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
